See the raw experimental evidence behind an author's publications and reproducibility signals.
Press Enter ↵ to solve
Fuel Your Discoveries
"A gene is a long sequence of coded letters, like computer information. Modern biology is becoming very much a branch of information technology."
- Richard Dawkins
Quick Explanation
Copied
Zachary J. Hauseman — evidence-based snapshot
Hauseman’s visible impact (OpenAlex) is consistent with structure-guided protein targeting and cellular mechanism validation across apoptosis/ubiquitin-family systems and RAS–MAPK signaling, including first-author work in Molecular Cell and Nature (see cited papers below).
Long Explanation
Author Review (Critical, evidence-focused): Zachary J. Hauseman
Scope note (epistemic humility): The input provides (i) an OpenAlex-derived profile/metrics and (ii) one richly described paper dataset (plus additional top-works metadata). I therefore review scientific strength only where the provided evidence allows, and I flag uncertainty where I cannot verify experimental details beyond the supplied excerpts.
VISUAL 1 — Publication & citation tempo (from supplied OpenAlex year buckets)
What this supports: Increased output/visibility around 2020–2022 (given buckets) aligns with major, high-profile venues for the top works listed.
What it cannot prove: Citations are a noisy proxy for scientific impact and are affected by field size, time-on-topic, and citation practices; causal inference is not justified.
Caution: “cited_by_count” is an OpenAlex metric and not the same as normalized citation impact. Treat it as directional.
VISUAL 3 — Example potency summary from the provided SHOC2–RAS paper dataset
The dataset includes TR-FRET IC50 and some SPR Kd values for select inhibitors (compounds 1,2,3,4,5,6,7). I plot only values explicitly provided.
Interpretation boundaries: IC50 and Kd are not directly interchangeable (assay formats differ). I’m treating this plot as descriptive, not mechanistic proof.
VISUAL 4 — Evidence stack for the provided SHOC2–RAS dataset (known vs uncertain)
“Not fully verified from excerpt” flags limits of the provided text—not a claim of missing experiments in the paper.
Core scientific strengths (grounded in the provided publication evidence)
1) Mechanism-to-structure-to-function pipeline
In the provided RAS–MAPK targeting work, the excerpt describes an integrated workflow: genetic dependency screens, biophysical/competition binding assays, X-ray crystallography of the SHOC2–RAS binary interface, and multiple cellular readouts (e.g., TR-FRET engagement, NanoBiT interaction disruption, and MAPK phosphorylation changes), culminating in xenograft tumor-growth effects in NRAS(Q61*) contexts. This triangulation pattern generally strengthens causal inference compared with single-modality studies alone.
2) Focus on “druggable interfaces” within protein complexes
Separate top-work metadata indicates structural work on the MRAS–SHOC2–PP1C phosphatase complex in Nature, which (based on its title/abstract snippet) targets mechanistic understanding of RAS signaling via RAF and the associated phosphatase assembly—again aligning with interface-centric mechanistic studies.
3) Breadth across apoptosis and ubiquitin-system chemistry
The provided OpenAlex top-works list includes (i) Molecular Cell work on BAX oligomers and mitochondrial membrane permeabilization structural determinants and (ii) chemistry/chemical biology work on covalent inhibitors via disulfide tethering for anti-apoptotic BFL-1 .
Critical assessment: where the scientific case is strong vs where uncertainty remains
Strong (from the provided SHOC2–RAS excerpt)
Multi-layer triangulation: genetic dependency + direct interaction assays + structural interface + cell signaling readouts + in vivo effect (as described in the excerpt) reduces the chance that a single artifact drives the conclusion.
Selectivity logic: the excerpt explicitly claims differential effects across NRAS(Q61*) vs BRAF(V600E) contexts and includes an “inactive” enantiomer (compound 7), which is an important experimental control class.
Uncertainty / potential blind spots (explicitly noted in the provided dataset text)
Preclinical context risk: cell-line and xenograft models may not fully recapitulate patient tumor microenvironments, heterogeneity, and pharmacology. The excerpt itself flags this as a limitation.
Off-target and systems-biology ambiguity: the excerpt acknowledges potential off-target effects of SHOC2 disruption and remaining uncertainty about comprehensive pathway consequences.
Interface generality: structural evidence and target engagement are presented in selected mutant contexts; broad applicability across all NRAS/KRAS Q61* (and other KRAS mutant states) would require additional evidence.
Correlation with citation/impact signals (and how to interpret them skeptically)
From the supplied OpenAlex snippet, Hauseman shows 209 cited-by and an h-index of 8 (OpenAlex). These are plausible indicators of community attention, but they cannot guarantee methodological quality per paper, and they are confounded by field size, venue visibility, and citation accumulation time.
For the specific SHOC2–RAS Nature paper, the dataset indicates it is cited (OpenAlex “cited_by_count” in the excerpt) and describes a multi-assay target-validation storyline consistent with high scrutiny. Still, citation counts are not substitutes for reading methods, controls, and replication attempts.
Targeted next steps for a sharper critique (BGPT actions)
Feedback:
Updated: April 07, 2026
BGPT Author Review
Scientific Quality
70%
Strength appears in mechanism-driven biochemical/structural/cellular integration (especially in the provided SHOC2–RAS Nature preclinical dataset), suggesting competence in target validation. However, the current review is constrained by missing full-method details for most papers, and preclinical translation limits (PK/PD, off-target, generality) are explicitly flagged in the provided dataset. Citation metrics presented are directional and not quality-adjusted.
Communication Quality
70%
The provided excerpts are structured and include assay/modality details, but the review here is limited because only one paper has rich textual extraction. A full evaluation of clarity/communication would require abstracts/full texts or additional extracted author-specific writing.
Author Novelty
70%
The SHOC2–RAS targeting and structural interface emphasis suggest a non-trivial orthogonal angle to direct RAS inhibition, but novelty relative to prior SHOC2/RAS interface work cannot be fully assessed from the provided excerpt alone.
Scientific Rigor
70%
The excerpt describes multiple independent evidence modalities (screens, binding assays, crystallography, cellular engagement, pathway readouts, and in vivo xenografts). Nonetheless, the provided dataset itself notes limitations (preclinical scope, incomplete PK/PD, possible off-targets, and long-term safety unknown), so rigor-to-translation is not yet closed.
No bioinformatics code is clearly required from the provided dataset; the key elements are potency tables and evidence flags already captured directly from the excerpt.
Get emailed when your analysis is done!
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
A simplistic “SHOC2 is always required for Ras signaling” hypothesis is less favored because the provided excerpt indicates selectivity across mutant contexts and implies dependency is genotype-specific rather than universal.
A “structural interface equals cellular causal mechanism” strongman is too strong: even with crystal structures and binding assays, off-target effects and network rewiring can produce pathway changes; the excerpt itself flags off-target and long-term uncertainty.
Quick Explanation
Long Explanation
Top Data Sources
ExportMCP
Keep Exploring
Analysis Wizard
Hypothesis Graveyard
Potential Experiments
Discussion
Fuel Your Discoveries
Ask a Follow-Up
Key Insight